A perspective on the emergence of meditation techniques for medical disorders

Journal of Alternative and Complementary Medicine

Volumn 12, Issue 8, 2006, Pages 709-713

  Shannahoff Khalsa, David ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Khalsa Foundation for Medical Science   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY DISORDER; EDITORIAL; MEDITATION; MOOD DISORDER; NEGATIVE SYNDROME; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; TREATMENT OUTCOME; YOGA;

CHRONIC DISEASE; HOLISTIC HEALTH; HUMANS; MEDITATION; MENTAL HEALING; MIND-BODY RELATIONS (METAPHYSICS); RESEARCH DESIGN;

EID: 33845575480     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2006.12.709     Document Type: Editorial

References (27)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40.
2. Rush AJ, Trivedi, MH, Wisniewski SR. et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. NEJM 2006;354:1231-1242.
3. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. NEJM, 2006;354:1243-1252.
4. Fava M, Rush AJ, Wisniewski SR, et al. A Comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. Am J Psychiatry 2006;163:1161-1172.
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM 2005;353:1209-1223.
6. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622.
7. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610.
8. Canter PH, Ernst E. Insufficient evidence to conclude whether or not Transcendental Meditation decreases blood pressure: Results of a systematic review of randomized clinical trials. J Hypertens 2004;22:2049-2054.
9. Jorm AF, Christensen H. Griffiths KM, et al. Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Aust 2004;181(7suppl):S29-S46.
10. Pilkington K, Kirkwood G, Rampes H, et al. Yoga for depression: The research evidence. J Affect Disord 2005;39:884-891.
11. Kirkwood G, Rampes H, Tuffrey V, et al. Yoga for anxiety: A systematic review of the research evidence. Br J Sports Med 2005;39:884-891.
12. Krisanaprakornkit T, Krisanaprakornkit W, Piyavhatkul N, Laopaiboon M. Meditation therapy for anxiety disorders. Cochrane Database Syst Rev 2006;1:CD004998.
13. Shannahoff-Khalsa D, Ray L, Levine S, et al. Randomized controlled trial of yogic meditation techniques for patients with obsessive compulsive disorders. CNS Spectrums 1999;4:34-46.
14. Menza M. STAR*D: The results begin to roll in. Am J Psychiatry 2006;163:1123.
15. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31.
16. Keefe RS. Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale. Schizophr Bull 2003;29:45-55.
17. Tamminga CA. Practical treatment information for schizophrenia. Am J Psychiatry 2006;163:563-565.
18. McEvoy JP, Meyer JM, Goff DV, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
19. Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273-1276.
20. Wallace RK. Physiological effects of Transcendental Meditation. Science 1970;167:1751-1754.
21. Benson H. The Relaxation Response. New York: William Morrow, 1975.
22. Kabat-Zinn J. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness. New York: Delacorte Press, 1990.
23. Shannahoff-Khalsa D. Kundalini Yoga meditation techniques in the treatment of obsessive compulsive and OC spectrum disorders. Brief Treatment and Crisis Intervention 2003;3:369-382.
24. Shannahoff-Khalsa DS. An introduction to Kundalini yoga meditation techniques that are specific for the treatment of psychiatric disorders. J Altern Complement Med 2004;10:91-101.
25. Shannahoff-Khalsa DS. Patient perspectives: Kundalini yoga meditation techniques for psycho-oncology and as potential therapies for cancer. Integr Cancer Ther 2005;4:87-100.
26. Brown RP, Gerbarg PL. Sudarshan Kriya Yogic breathing in the treatment of stress, anxiety, and depression: Part II-clinical applications and guidelines. J Altern Complement Med 2005;11:711-717.
27. Shannahoff-Khalsa D. Kundalini Yoga Meditation: Techniques Specific for Psychiatric Disorders, Couples Therapy, and Personal Growth. New York & London: W.W. Norton & Co., 2006.